Letter: the safety of herpes zoster vaccination for patients with inflammatory bowel disease being treated with anti-TNF medications
Aliment Pharmacol Ther
.
2018 Feb;47(3):446-447.
doi: 10.1111/apt.14435.
Authors
J Côté-Daigneault
1
,
M L Luong
2
,
J-F Colombel
3
,
F Peerani
4
Affiliations
1
Division of Gastroenterology, CHUM/CRCHUM, University of Montreal, Quebec, Canada.
2
Division of Microbiology and Infectious Diseases, CHUM, University of Montreal, Quebec, Canada.
3
The Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine, New York, NY, USA.
4
Division of Gastroenterology, University of Alberta, Alberta, Canada.
PMID:
29314127
DOI:
10.1111/apt.14435
No abstract available
Publication types
Letter
Comment
MeSH terms
Herpes Zoster
Humans
Inflammatory Bowel Diseases*
Tumor Necrosis Factor-alpha*
Vaccination
Substances
Tumor Necrosis Factor-alpha